We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+10.01%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$111M
AUM Growth
+$2.3M
Cap. Flow
+$4.8M
Cap. Flow %
4.31%
Top 10 Hldgs %
45.14%
Holding
70
New
3
Increased
23
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
BIVV
Bioverativ Inc. Common Stock
BIVV
+$648K
2
UTHR icon
United Therapeutics
UTHR
+$525K
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$509K
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$340K
5
SGEN
Seagen Inc. Common Stock
SGEN
+$316K

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$613K
2
MYGN icon
Myriad Genetics
MYGN
+$527K
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$404K
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$220K
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$140K

Sector Composition

Rank Sector Weight
1 Healthcare 73.61%
2 Miscellaneous 26.05%
3 Real Estate 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CKPT
51
DELISTED
Checkpoint Therapeutics
CKPT
$507K 0.45%
11,276
-500
-4% -$43.4K
UTHR icon
52
United Therapeutics
UTHR
$22.6B
$481K 0.43%
+4,108
New +$525K
PGEN icon
53
Precigen
PGEN
$2.57B
$455K 0.41%
23,928
+5,583
+30% +$115K
AKBA icon
54
Akebia Therapeutics
AKBA
$260M
$413K 0.37%
21,009
– –
SNR
55
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$383K 0.34%
41,850
– –
ICPT
56
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$260K 0.23%
4,481
+2,661
+146% +$287K
HRTX icon
57
Heron Therapeutics
HRTX
$63M
$256K 0.23%
15,874
– –
AVXS
58
DELISTED
AveXis, Inc. Common Stock
AVXS
$242K 0.22%
2,500
– –
SCTL
59
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$227K 0.2%
28,133
– –
LGND icon
60
Ligand Pharmaceuticals
LGND
$5.67B
$207K 0.19%
2,435
-952
-28% -$75.4K
CFRX
61
DELISTED
ContraFect Corporation
CFRX
$167K 0.15%
188
– –
SCYX icon
62
SCYNEXIS
SCYX
$54.9M
$161K 0.14%
833
– –
PGNX
63
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$160K 0.14%
21,782
– –
BIB icon
64
PUT
ProShares Ultra NASDAQ Biotechnology
BIB
$105M
– –
-42,500
Closed -$2.27M
IBB icon
65
PUT
iShares Biotechnology ETF
IBB
$10.8B
– –
-37,500
Closed -$3.88M
IOVA icon
66
Iovance Biotherapeutics
IOVA
$3.74B
– –
-29,934
Closed -$220K
MYGN icon
67
Myriad Genetics
MYGN
$304M
– –
-20,414
Closed -$527K
XBI icon
68
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
– –
-65,000
Closed -$5.02M
SIOX
69
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-2,178
Closed -$404K
KITE
70
DELISTED
Kite Pharma, Inc.
KITE
– –
-5,915
Closed -$613K
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2017 Portfolio in Review

As of Q3 2017, Opus Point Partners Management held 70 positions worth $111M, up 2.1% from $109M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Opus Point Partners Management deployed $4.8M of net new capital in Q3 2017, opening 3 new positions and adding to 23 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 11,056 shares worth $631K.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $140K trimmed.

  • Opus Point Partners Management's largest Q3 2017 buy was Bioverativ Inc. Common Stock: 11,056 shares worth $631K.
  • Opus Point Partners Management added most to Ultragenyx Pharmaceutical in Q3 2017, an estimated $340K increase.
  • Opus Point Partners Management's biggest Q3 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $140K.
  • Opus Point Partners Management fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $613K.
  • Opus Point Partners Management's ten largest holdings make up 45% of its $111M portfolio in Q3 2017.
  • Opus Point Partners Management opened 3 new positions and closed 7 in Q3 2017.
  • Opus Point Partners Management's portfolio value rose 2.1% quarter-over-quarter to $111M.

Based on Opus Point Partners Management's 13F filing for Q3 2017, filed 14 Nov 2017.